LADYX | Developing Growth Fund Class I | Lord Abbett

Tracked Funds

You have 0 funds on your mutual fund watch list.

Begin by selecting funds to create a personalized watch list.

(as of 12/05/2015)

Pending Orders

You have 0 items in your cart.

Subscribe and order forms, fact sheets, presentations, and other documents that can help advisers grow their business.

 

Developing Growth Fund

Track this Fund
Add to Hypo Tool

Summary

Summary

What is the Developing Growth Fund?

The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of small U.S. companies.

Fund Basicsas of 03/28/2024

Total Net Assets
$2.58 B
Inception Date
12/30/1997
Dividend Frequency
Annually
Fund Gross Expense Ratio
0.67%
Fund Net Expense Ratio
0.67%
Number of Holdings
78
Minimum Initial Investment

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 12/30/1997
w/o sales charge 12.70% 13.07% -9.01% 6.65% 8.11% 8.64%
Lipper Category Avg. Small-Cap Growth Funds 8.42% 19.11% -1.53% 8.92% 8.85% -
Russell 2000® Growth Index 7.58% 20.35% -2.68% 7.38% 7.89% 6.82%
w/ sales charge 12.70% 13.07% -9.01% 6.65% 8.11% 8.64%

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 12/30/1997
w/o sales charge 12.70% 13.07% -9.01% 6.65% 8.11% 8.64%
Lipper Category Avg. Small-Cap Growth Funds 8.42% 19.11% -1.53% 8.92% 8.85% -
Russell 2000® Growth Index 7.58% 20.35% -2.68% 7.38% 7.89% 6.82%

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

TEN LARGEST HOLDINGS as of 03/28/2024View Portfolio

Holding Assets
Cava Group Inc 2.5%
Wingstop Inc 2.2%
Trex Co Inc 2.2%
Comfort Systems USA Inc 2.1%
AeroVironment Inc 2.1%
Saia Inc 2.1%
Blueprint Medicines Corp 2.0%
CyberArk Software Ltd 2.0%
Glaukos Corp 2.0%
RxSight Inc 1.9%

INVESTMENT TEAM

F. Thomas O'Halloran
F. Thomas O'Halloran, CFA, J.D.

Partner, Portfolio Manager

37 Years of Industry Experience

Matthew R. DeCicco
Matthew R. DeCicco, CFA

Partner & Director of Equities

23 Years of Industry Experience

Vernon Bice
Vernon Bice, CMT

Portfolio Manager

23 Years of Industry Experience

Benjamin Ebel
Benjamin Ebel

Senior Managing Director, Portfolio Manager

32 Years of Industry Experience

Supported By 10 Investment Professionals with 17 Years Avg. Industry Experience

Your Representative

To contact your representative, enter your zip code and select your channel below.

Performance

Performance

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 12/30/1997
w/o sales charge 12.70% 13.07% -9.01% 6.65% 8.11% 8.64%
Lipper Category Avg. Small-Cap Growth Funds 8.42% 19.11% -1.53% 8.92% 8.85% -
Russell 2000® Growth Index 7.58% 20.35% -2.68% 7.38% 7.89% 6.82%
w/ sales charge 12.70% 13.07% -9.01% 6.65% 8.11% 8.64%

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

YTD 1-YR 3-YR 5-YR 10-YR Since Inception 12/30/1997
w/o sales charge 12.70% 13.07% -9.01% 6.65% 8.11% 8.64%
Lipper Category Avg. Small-Cap Growth Funds 8.42% 19.11% -1.53% 8.92% 8.85% -
Russell 2000® Growth Index 7.58% 20.35% -2.68% 7.38% 7.89% 6.82%

Fund Expense Ratio :

Gross 0.67%

Net 0.67%

Year Fund Returns Russell 2000® Growth Index
2023 8.74% 18.66%
2022 -35.92% -26.36%
2021 -2.41% 2.83%
2020 72.95% 34.63%
2019 32.25% 28.48%
2018 5.37% -9.31%
2017 30.27% 22.17%
2016 -2.48% 11.32%
2015 -8.64% -1.38%
2014 3.56% 5.60%
2013 57.77% -
2012 10.73% -
2011 -1.30% -
2010 37.01% -
2009 47.54% -
2008 -47.31% -
2007 36.29% -
2006 12.86% -
2005 12.31% -
2004 6.39% -
Year Q1 Q2 Q3 Q4
2024 12.70% - - -
2023 8.39% 3.31% -12.94% 11.55%
2022 -19.22% -21.10% 0.68% -0.13%
2021 1.72% 2.93% -3.63% -3.28%
2020 -16.89% 40.70% 15.98% 27.53%
2019 27.04% 9.18% -11.29% 7.48%
2018 7.20% 15.07% 12.25% -23.90%
2017 8.45% 4.10% 7.18% 7.67%
2016 -10.24% 2.28% 10.94% -4.25%
2015 7.18% 2.69% -15.63% -1.62%
2014 1.76% 0.24% -5.71% 7.66%
2013 13.60% 10.13% 18.88% 6.09%
2012 12.24% -2.59% 5.66% -4.16%
2011 10.32% 1.61% -20.78% 11.16%
2010 8.25% -7.85% 16.61% 17.79%
2009 -2.06% 24.50% 14.24% 5.91%
2008 -21.75% 6.69% -11.69% -28.53%
2007 4.75% 13.67% 9.96% 4.10%
2006 16.07% -6.14% -6.74% 11.08%
2005 -5.76% 5.86% 9.71% 2.62%
2004 2.15% 0.26% -6.94% 11.64%
2003 -3.21% 21.50% 9.82% 8.80%
2002 0.13% -11.79% -23.72% 5.00%
2001 -17.33% 16.13% -22.60% 25.77%
2000 3.54% -13.66% -0.45% -7.36%
1999 1.48% 11.84% -3.36% 26.59%
1998 11.63% -2.88% -21.97% 28.41%

NAV Historical Prices

Date Net Asset Value

Portfolio

Portfolio

Portfolio Positioning as of 03/31/2024

  • We believe the pressure on stock market valuations from the post-pandemic inflation surge and the Fed’s aggressive tightening is at an end, removing a major headwind for innovation stocks. While the decline in inflation has not been linear, several indicators suggest a continued downward bias. The remaining exception being a strong labor market, which has mixed implications, as higher real wages support consumer spending and a soft landing, while higher service prices should keep the Fed vigilant. Against this backdrop, we see stable economic growth and a low probability of a severe recession.
  • Thus far in 2024, unique areas of the U.S. economy are seeing differentiated growth and operating momentum relative to the broader market, creating a large dispersion in stock performance. The “Magnificent 7” from 2023 has given way to a much broader set of secular winners across and within industries. We continue to focus on these companies, as we believe their expanding markets, combined with market-share gains, pricing power, and efficiency-driven margin expansion, support above average revenue and earnings growth despite a modestly mixed and evolving global macro backdrop. At some point soon, we also envision a great number of smaller capitalized stocks to begin to outperform after a long period of underperformance.
  • Looking ahead, we are focused on several themes that we believe provide attractive long-term growth potential due to secular forces at play. These include, but are not limited to, generative artificial intelligence, the continued shift from offline consumption to online services, the proliferation of and improved use cases within medical devices, revolutionary advances in medical treatments and genomics technology, an industrial infrastructure reinvestment cycle driven by datacenter, electric grid, and supply chain reshoring, and a continuation of innovation in our consumer society. We are levered to these themes across our portfolios through companies that are seeing outsized growth because of one or more of these durable trends

Dividends & Cap Gains

Dividends & Cap Gains

Upcoming Dividend Payment Dates

This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.

Record Date Ex-Dividend Date Reinvest & Payable Date
11/25/2024 11/26/2024 11/26/2024

Capital Gains Distributions

For
Record Date Reinvest & Payable Date Long-term Short-term * Total Reinvest Price
11/22/2021 11/23/2021 $3.3406 - $3.3406 $36.00

Fees & Expenses

Fees & Expenses

Expense Ratioas of 03/31/2024

Fund Gross Expense Ratio Fund Net Expense Ratio
0.67% 0.67%

Fund Documents

Fund Documents

0Documents selected
Portfolio Holdings 1Q
Publish Date:11/03/2015
Portfolio Holdings 3Q
Publish Date:11/03/2015
Summary Prospectus
Publish Date:11/03/2015
Statutory Prospectus
Publish Date:11/03/2015
SAI
Publish Date:11/03/2015
Annual Report
Publish Date:11/03/2015
Semi-Annual Report
Publish Date:11/03/2015
Fact Sheet
Publish Date:11/03/2015
Commentary
Publish Date:11/03/2015
Fund Story
Publish Date:11/03/2015

To order literature visit full website

You may add to your cart by selecting quantities in each row below.

No rows selected. Please Go back and select at least one fund document

 
Quantity
Quantity
Remove
Remove

The Russell 2000® Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted growth values.

Select funds to run a Morningstar Hypothetical Report.

    Please confirm your literature shipping address

    Please review the address information below and make any necessary changes.

    All literature orders will be shipped to the address that you enter below. This information can be edited at any time.

    Current Literature Shipping Address

    * Required field